Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
(NY:
MAIA
)
3.368
+0.248 (+7.95%)
Streaming Delayed Price
Updated: 1:55 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about MAIA
< Previous
1
2
3
Next >
MAIA Biotechnology to Present Latest Findings for Second Generation THIO Program at Turkish Biochemical Society’s International Biochemistry Congress 2023
October 17, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Reveals New Data Showing THIO’s Potent Anticancer Activity in Aggressive Pediatric Brain Cancer
October 12, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Accelerates Enrollment in THIO-101 Phase II Clinical Trial as Efficacy Is Observed in Dosed Patients
October 10, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Announces Potent Anticancer Activity of THIO in Gliomas
October 10, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Announces FDA Clearance of IND Application for THIO, a First-in-Class Telomere Targeting Agent for the Treatment of Non-Small Cell Lung Cancer
October 03, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Announces Share Repurchase Program
September 28, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Reports Second Quarter 2023 Financial Results and Provides Updates for THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer
August 08, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Reports Updates on Disease Control Rates for THIO-101 Phase 2 Trial for Advanced Non-Small Cell Lung Cancer
July 11, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Reports Updates on Preliminary Survival Data for THIO-101 Phase 2 Trial for Advanced Non-Small Cell Lung Cancer
July 10, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Announces Updates in Enrollment in Phase II Clinical Trial: THIO-101 Has Enrolled 29 Patients
June 20, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Files Second Patent For New Telomere-Targeting Molecules Program
June 07, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 08, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology, Inc. Announces Closing of Public Offering
April 27, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology, Inc. Announces Pricing of Public Offering
April 24, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Reports Preliminary Survival Data in Part A of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer
April 20, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Announces Excellent Efficacy of THIO in Liver Cancer Models
April 18, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology to Present at AACR Annual Meeting 2023
April 12, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Reports Positive Topline Data from Part A Safety Lead-In of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer
April 11, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Reports Full Year 2022 Financial Results and Provides Corporate Update
March 24, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Announces No Exposure to Silicon Valley Bank
March 13, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Doses First Patients in Europe in Ongoing Phase 2 Trial (THIO-101) Evaluating THIO for Non-Small Cell Lung Cancer Treatment
March 07, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
ADDING MULTIMEDIA: MAIA Biotechnology’s Telomere-targeting Agent THIO, in Combination With Checkpoint Inhibitor Immune Therapies Atezolizumab (anti-PD-L1) or Pembrolizumab (anti-PD-1), Demonstrated Significantly Greater Tumor Inhibition
February 13, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
Sidoti's January Micro-Cap Conference
January 17, 2023
Via
ACCESSWIRE
MAIA Biotechnology Advances New Telomere-Targeting Molecule Program
January 17, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology to Participate in Four Upcoming Investor Conferences
January 05, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Holds Successful Pre-IND Meeting with FDA for Planned US Expansion of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer
December 20, 2022
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Expands Phase 2 THIO-101 Trial to Europe
December 13, 2022
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Announces Establishment of Rule 10b5-1 Trading Plan
November 22, 2022
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Presents Preclinical Data at SITC Annual Meeting Validating Efficacy of THIO in Treating Hepatocellular Carcinoma
November 15, 2022
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 09, 2022
From
MAIA Biotechnology, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.